Drug intelligence / Profile preview

ankerei

Development stage: Preclinical
Lead developer: Shanghai Skin Disease Hospital
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
Administration: Injection

Overview

Ankerei is a recombinant human adenovirus type 5 injection. It is being investigated in clinical studies for its efficacy and safety, particularly in combination with PD-1 monoclonal antibody and anti-vascular drugs, for the treatment of advanced malignant melanoma with liver metastasis. As a recombinant adenovirus, it is designed to selectively infect and replicate within cancer cells, leading to their lysis and potentially stimulating an anti-tumor immune response.

Other names: recombinant human adenovirus type 5 injection安柯瑞（重组人5型腺病毒注射液）

Beyond the preview

Go deeper on ankerei.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ankerei.

Explore the full profile